
Michael Ulz
Stock Analyst at Morgan Stanley
(0.68)
# 4,266
Out of 5,189 analysts
609
Total ratings
39%
Success rate
-1.7%
Average return
Main Sectors:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics | Reiterated: Buy | $61 | $27.42 | +122.47% | 2 | Nov 20, 2026 | |
| ADRX ADARx Pharmaceuticals | Maintained: Buy | $32 | $12.79 | +150.20% | 2 | Nov 16, 2026 | |
| AARD Aardvark Therapeutics | Maintained: Sell | $3 | $0.9226 | +225.17% | 11 | Nov 16, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintained: Hold | $5 | $1.95 | +156.41% | 21 | Nov 16, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | $95 | $24.77 | +283.53% | 29 | Nov 16, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Reiterated: Buy | $120 → $106 | $41.37 | +156.22% | 29 | Nov 13, 2026 | |
| ATTO Attovia Therapeutics | Reiterated: Buy | $40 | $15.10 | +164.90% | 1 | Nov 10, 2026 | |
| IONS Ionis Pharmaceuticals | Rated: Buy | $104 → $75 | $26.58 | +182.17% | 42 | Nov 10, 2026 | |
| VIR Vir Biotechnology | Reiterated: Buy | $25 → $28 | $8.39 | +233.73% | 26 | Nov 10, 2026 | |
| ZNTL Zentalis Pharmaceuticals | Rated: Hold | $5 | $1.36 | +267.65% | 14 | Nov 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $0.9361 | +1,288.74% | 23 | Nov 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $36 | $15.50 | +132.26% | 27 | Nov 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $25 | $13.33 | +87.55% | 32 | Nov 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 | $26.36 | +44.16% | 1 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $152 | $96.13 | +58.12% | 28 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $34 | $8.34 | +307.67% | 1 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $150 → $146 | $112.36 | +29.94% | 23 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $28 | $5.45 | +413.76% | 2 | Nov 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $300 → $240 | $143.82 | +66.88% | 51 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $146 → $150 | $115.31 | +30.08% | 2 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $24 → $4 | $0.82 | +387.80% | 21 | Oct 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $33 | $4.26 | +674.65% | 24 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $25 → $32 | $19.81 | +61.53% | 34 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $23 → $20 | $4.28 | +367.29% | 16 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.2866 | +597.84% | 15 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $0.39 → $0.36 | $0.000001 | +35,999,900.00% | 13 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $7.56 | n/a | 8 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $0.919 | n/a | 13 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $20 → $5 | $9.41 | n/a | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $0.5 | $1.28 | n/a | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.77 | n/a | 3 | Dec 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $40 | $33.31 | n/a | 12 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $60 → $23 | $6.90 | n/a | 2 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3 | $3.72 | n/a | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 → $3 | $20.73 | n/a | 2 | Jan 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $60.41 | n/a | 15 | Mar 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.3698 | n/a | 12 | Mar 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $25.56 | n/a | 2 | Mar 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $22.15 | n/a | 2 | Mar 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.48 | n/a | 13 | Mar 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $340 | $925.70 | n/a | 6 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $69 → $60 | $7.45 | n/a | 2 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $12.85 | n/a | 3 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.41 | n/a | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 | $8.72 | n/a | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $45 | $7.36 | n/a | 1 | Aug 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 → $8 | $0.00001 | n/a | 4 | Jul 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $40 | $2.28 | n/a | 5 | Mar 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $3.58 | n/a | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $166.43 | n/a | 1 | May 18, 2010 |
Celldex Therapeutics
Nov 20, 2026
Reiterated: Buy
Price Target: $61
Current: $27.42
Upside: +122.47%
ADARx Pharmaceuticals
Nov 16, 2026
Maintained: Buy
Price Target: $32
Current: $12.79
Upside: +150.20%
Aardvark Therapeutics
Nov 16, 2026
Maintained: Sell
Price Target: $3
Current: $0.9226
Upside: +225.17%
Rocket Pharmaceuticals
Nov 16, 2026
Maintained: Hold
Price Target: $5
Current: $1.95
Upside: +156.41%
Viking Therapeutics
Nov 16, 2026
Reiterated: Buy
Price Target: $95
Current: $24.77
Upside: +283.53%
Arrowhead Pharmaceuticals
Nov 13, 2026
Reiterated: Buy
Price Target: $120 → $106
Current: $41.37
Upside: +156.22%
Attovia Therapeutics
Nov 10, 2026
Reiterated: Buy
Price Target: $40
Current: $15.10
Upside: +164.90%
Ionis Pharmaceuticals
Nov 10, 2026
Rated: Buy
Price Target: $104 → $75
Current: $26.58
Upside: +182.17%
Vir Biotechnology
Nov 10, 2026
Reiterated: Buy
Price Target: $25 → $28
Current: $8.39
Upside: +233.73%
Zentalis Pharmaceuticals
Nov 10, 2026
Rated: Hold
Price Target: $5
Current: $1.36
Upside: +267.65%
Nov 6, 2026
Reiterated: Buy
Price Target: $13
Current: $0.9361
Upside: +1,288.74%
Nov 6, 2026
Rated: Buy
Price Target: $36
Current: $15.50
Upside: +132.26%
Nov 6, 2026
Rated: Hold
Price Target: $25
Current: $13.33
Upside: +87.55%
Nov 5, 2026
Reiterated: Buy
Price Target: $38
Current: $26.36
Upside: +44.16%
Nov 5, 2026
Rated: Buy
Price Target: $152
Current: $96.13
Upside: +58.12%
Nov 5, 2026
Rated: Buy
Price Target: $34
Current: $8.34
Upside: +307.67%
Nov 4, 2026
Reiterated: Buy
Price Target: $150 → $146
Current: $112.36
Upside: +29.94%
Nov 2, 2026
Rated: Buy
Price Target: $28
Current: $5.45
Upside: +413.76%
Oct 30, 2026
Rated: Hold
Price Target: $300 → $240
Current: $143.82
Upside: +66.88%
Oct 30, 2026
Rated: Buy
Price Target: $146 → $150
Current: $115.31
Upside: +30.08%
Oct 19, 2026
Reiterated: Hold
Price Target: $24 → $4
Current: $0.82
Upside: +387.80%
Aug 12, 2026
Rated: Buy
Price Target: $33
Current: $4.26
Upside: +674.65%
Aug 11, 2026
Rated: Buy
Price Target: $25 → $32
Current: $19.81
Upside: +61.53%
Aug 7, 2026
Reiterated: Hold
Price Target: $23 → $20
Current: $4.28
Upside: +367.29%
Jun 3, 2026
Reiterated: Buy
Price Target: $2
Current: $0.2866
Upside: +597.84%
Jan 8, 2026
Downgraded: Sell
Price Target: $0.39 → $0.36
Current: $0.000001
Upside: +35,999,900.00%
Mar 11, 2025
Reiterated: Buy
Price Target: $5
Current: $7.56
Upside: n/a
Mar 6, 2025
Reiterated: Hold
Price Target: $5
Current: $0.919
Upside: n/a
Feb 11, 2025
Downgraded: Hold
Price Target: $20 → $5
Current: $9.41
Upside: n/a
Aug 13, 2024
Reiterated: Sell
Price Target: $0.5
Current: $1.28
Upside: n/a
Dec 15, 2023
Rated: Hold
Price Target: n/a
Current: $1.77
Upside: n/a
Aug 22, 2023
Reiterated: Hold
Price Target: $40
Current: $33.31
Upside: n/a
May 22, 2023
Rated: Buy
Price Target: $60 → $23
Current: $6.90
Upside: n/a
Jan 27, 2023
Downgraded: Hold
Price Target: $3
Current: $3.72
Upside: n/a
Jan 5, 2022
Reiterated: Hold
Price Target: $7 → $3
Current: $20.73
Upside: n/a
Mar 12, 2021
Rated: Hold
Price Target: n/a
Current: $60.41
Upside: n/a
Mar 12, 2021
Rated: Hold
Price Target: n/a
Current: $0.3698
Upside: n/a
Mar 12, 2021
Rated: Hold
Price Target: n/a
Current: $25.56
Upside: n/a
Mar 12, 2021
Rated: Hold
Price Target: n/a
Current: $22.15
Upside: n/a
Mar 12, 2021
Rated: Hold
Price Target: n/a
Current: $16.48
Upside: n/a
Mar 4, 2021
Reiterated: Buy
Price Target: $340
Current: $925.70
Upside: n/a
Mar 1, 2021
Reiterated: Hold
Price Target: $69 → $60
Current: $7.45
Upside: n/a
Feb 16, 2021
Reiterated: Buy
Price Target: n/a
Current: $12.85
Upside: n/a
Jan 29, 2021
Reiterated: Buy
Price Target: $5
Current: $1.41
Upside: n/a
Jan 29, 2021
Reiterated: Buy
Price Target: $37
Current: $8.72
Upside: n/a
Aug 12, 2020
Initiated Coverage: Buy
Price Target: $45
Current: $7.36
Upside: n/a
Jul 30, 2020
Reiterated: Buy
Price Target: $15 → $8
Current: $0.00001
Upside: n/a
Mar 28, 2019
Reiterated: Hold
Price Target: $3 → $40
Current: $2.28
Upside: n/a
Oct 3, 2017
Rated: Buy
Price Target: n/a
Current: $3.58
Upside: n/a
May 18, 2010
Reiterated: Buy
Price Target: $28
Current: $166.43
Upside: n/a